Pay in 4 interest-free payments of $5.16 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Peer review Peer review information Nature Reviews Endocrinology thanks Michael Falster, who co-reviewed with Tamara Milder
The litigation targets GLP-1 receptor agonist medications, a class of drugs originally developed for type 2 diabetes that became massively popular for weight loss
Some specific proteins, such as PA28, PA28, and PA200, that act as proteasome regulatory particles can drive Substrate degradation through ubiquitin-independent mechanisms in the 20S proteasome [16,17,18]
Movement also matters
US$ 27.40
US$ 28.69
US$ 24.99
